ArticleBMC cancer2026
Lipid-dominated metabolites mediate the association between low body mass index and esophageal malignancy: a population-based nested case-control study.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
backgroundThe biological mechanism underlying the association between low body mass index (BMI) and increased risk of esophageal malignancy remains uncertain. We aimed to explore the role of metabolic alterations in the effect of low BMI on esophageal malignancy.
methodsWe conducted a nested case-control study using a large-scale community-based screening cohort in a high-risk region for esophageal cancer (263 cases and 263 matched controls). Metabolomic profiling was performed based on untargeted ultra-high-performance liquid chromatography-tandem mass spectrometry, using the serum samples collected at enrollment prior to cancer diagnosis. Linear regression and conditional logistic regression were used to identify BMI-related metabolites and metabolites associated with esophageal malignancy, respectively, and the shared metabolites were included in mediation analysis.
resultsLow BMI was positively associated with esophageal malignancy (odds ratio (OR) = 1.8 (95% confidence interval: 1.1-2.8)). A total of 160 metabolites were identified to be associated with low BMI, and 107 metabolites were associated with esophageal malignancy. Among the 21 shared metabolites, four metabolites (three lipids and one amino acid) were identified as mediators for the association between low BMI and esophageal malignancy, with the mediation effect (OR) of 1.1 for each mediator. The metabolic signature constructed based on these mediators could explain 46.0% of the effect of low BMI on esophageal malignancy.
conclusionsLipid-dominated metabolites mediate the association between low BMI and esophageal malignancy, which has provided crucial clues for understanding the etiology of esophageal malignancy and selection of early-warning metabolic biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.